



**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Winrevair™ (sotatercept-csrk)

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER:

Male

Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY

1. Does the patient have pulmonary arterial hypertension (PAH) WHO group 1? Yes No

2. Has the diagnosis been confirmed by right heart catheterization? Yes No

If yes, provide documentation.

3. Provide the following values attached or in the space provided.

Pulmonary arterial pressure: _____

Pulmonary capillary wedge pressure: _____

Pulmonary vascular resistance: _____

4. Is the patient's PAH considered functional class II or greater? Yes No

Phone: 1-866-675-7755

Fax: 1-888-603-7696

© 2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 06/05/2025





**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Winrevair™ (sotatercept-csrk)

DATE OF MEDICATION REQUEST: / /

5. Has the patient been on stable background PAH therapy for at least 90 days? Yes No
If yes, list the medications and start dates.

6. Is the patient a female of reproductive potential? Yes No
If yes, will pregnancy be ruled out before therapy begins? Yes No

Will the patient be educated on contraceptive needs during therapy and for at least 4 months after therapy ends? Yes No

7. Will hemoglobin and platelets be monitored throughout therapy? Yes No
Provide the baseline platelet count: _____

8. Is the prescriber a cardiologist or pulmonologist, or has one been consulted? Yes No

RENEWAL:

1. Has the patient experienced any treatment-restricting adverse effects? Yes No

2. Has the patient benefited from the medication through disease improvement, stabilization, or improvement in the slope of decline? Yes No

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ **DATE:** _____